Concord Biotech Limited
Concord Biotech Limited (CONCORDBIO.BO) Stock Overview
Explore Concord Biotech Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
107.3B
P/E Ratio
34.37
EPS (TTM)
$29.75
ROE
0.18%
CONCORDBIO.BO Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Concord Biotech Limited (CONCORDBIO.BO) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 33.20, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1893.35.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 34.37 and a market capitalization of 107.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.